[A new intrauterine device with progesterone for control of reproduction]. / Osservazioni sul nuovo dispositivo intrauterino al progesterone per il controllo della riproduzione.

PIP: The article reports on 33 insertions of the progesterone-releasing IUD, Progestasert, in patients aged 17-45 with an average age of 31; most patients had 2 children. Insertion of the device was easy, and the device itself was extremely well tolerated; 12 of the original 33 patients carried the device for more than 24 months, and 5 carried it for more than 36 months. There were no pregnancies, 2 cases of spontaneous expulsion, 2 removals for pelvic pain, and 2 for desire of pregnancy. Not only were there no side effects, but a positive action of the device was noted against genital inflammation, together with marked improvement of mammary tension and intramenstrual occurrence of headache. Vaginal cytology remained normal or it improved.^ieng

[Clinical experience with two low dosage estrogen progestogen preparations (SH 7.1122 and SH B 259 AB)]. / Sperimentazione clinica di due preparati estro-progestinici a basso dosaggio siglati SH 7.112 e SH B 259 AB.

PIP: Authors have clinically experimented with 2 new low dosage estrogen/progestogen (OCs) oral contraceptives: SH 7.1122 containing NEA 1 mg and EE 0.03 mg; SH B 259 AB containing NEA 2 mg and EE 0.03 mg. Drugs have been shown to control very well cycle and menstrual bleeding with an incidence of collateral effects similar to other oral combined estrogen/progestogen pills. Besides a diminishing incidence of dysmenorrhea, mammary tensions have been reported mostly in patients treated with SH B 259 AB. (Author's )^ieng

"Uterine progesterone system (U.P.S.)": a new form of intrauterine contraception. Preliminary report.

PIP: This preliminary study of the "uterine progesterone system" (UPS), a new contraceptive agent, on 32 women for a total of 200 woman-months was very effective. There were no side effects, no expulsions, no pregnancies, and no abnormalities in the metabolism of fats, carbohydrates and protein. The UPS is in the shape of a T which is easily inserted and easily removed. It has a biocompatible polymer outer membrane containing an inner core of progesterone suspension. The UPS releases 50 mcg of progesterone per 24 hours for more than a year. The local release of steroids interferes with fertility but does not affect the hypothalamic-pituitary-ovarian axis.^ieng